D2B3 is a pre-clinical biotechnology company dedicated to advancing drug delivery solutions to the brain and central nervous system. Its proprietary technology allows to transiently and specifically open the blood brain barrier for therapeutic targeting of CNS diseases with high efficacy. Our approach is plug-and-play and works with most drugs and therapeutic classes.
| Website | https://d2b3.bio |
| Employees | 3 (1 on RocketReach) |
| Address | 101 College St, New Haven, Connecticut 06510, US |
| Industry | Biotechnology Research |
| Keywords | Drug Delivery, Targeted Drug Delivery, Central Nervous System, Therapeutic Drug Delivery, Drug Development, Innovative Drug Delivery, Preclinical Research, Neurological Therapeutics, Biotechnology, Pharmaceutical Research, Pharmaceutical Technology, Transdermal Drug Delivery, Nanomedicine |
Looking for a particular D2B3 employee's phone or email?
Manuel Mohr is the Co-Founder and CEO of D2B3.
1 people are employed at D2B3.
D2B3 is based in New Haven, Connecticut.